# A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

> **NCT07643155** · PHASE1 · RECRUITING · sponsor: **Insmed Incorporated** · enrollment: 30 (estimated)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder

## Key facts

- **NCT ID:** NCT07643155
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-14
- **Primary completion:** 2027-02-07
- **Final completion:** 2027-02-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643155, "A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*